Novavax CEO Rahul Singhvi – An Interview With “The Pink Sheet” DAILY, Part 3 of 3
This article was originally published in The Pink Sheet Daily
Executive Summary
Novavax execs discuss alternatives to injectable vaccines and how the vaccine industry is changing.
You may also be interested in...
Pfizer Taps Into Cytos’ Vaccine Pipeline
Licensing deal for $10 million upfront includes access to novel Immunodrug technology that uses virus like particles.
Pfizer Taps Into Cytos’ Vaccine Pipeline
Licensing deal for $10 million upfront includes access to novel Immunodrug technology that uses virus like particles.
Novavax CEO Rahul Singhvi – An Interview With “The Pink Sheet” DAILY, Part 2 of 3
Novavax execs describe the firm's Virus Like Particle technology and how disposable, egg-less virus manufacturing is changing the industry.